Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures

Impact · against what's priced in

Alumis shares are likely to see a positive catalyst as the company confirms its 4Q 2026 NDA submission timeline and presents superior PASI 100 efficacy data. The demonstration of success in difficult-to-treat areas like the scalp and the absence of new safety signals strengthen the drug's competitive positioning in the oral psoriasis market.

ALMS+0.70

No priced-in read yet